Products are for research use only, not for human use

Compound research hub

Ipamorelin: Research, Handling and Batch Documentation

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide agonist at the growth hormone secretagogue receptor, GHS-R1a.

Part of Volta's peptides.

Identity and specification

Form
Lyophilized powder
Appearance
White lyophilised powder
Compound class
Growth hormone secretagogue receptor (GHS-R1a) agonist
CAS number
170851-70-4
Molecular formula
C₃₈H₄₉N₉O₅
Molecular weight
711.85 g/mol
PubChem CID
9831659
Production
Synthetic, by solid-phase peptide synthesis
Solubility
Soluble in sterile water
Shelf life
24 months from date of manufacture

Molecular structure, sequence and the published laboratory studies on Ipamorelin are in the compound library entry for Ipamorelin.

Vial sizes available

Every size of Ipamorelin Volta lists, in stock or not. Each is a separate catalogue page with its own batch number and specification table.

Purity and batch documentation

Volta's release specification is >99% (HPLC). That is a threshold we set. >99% is the specification every batch is released to. The figure on a certificate is what a laboratory measured for one lot.

Research on Ipamorelin

Handling and stability

Regulatory context

Ipamorelin in Canada

Ipamorelin is not authorized for sale in Canada or anywhere else. No regulator has approved it for any indication, and no approved ipamorelin product exists.

  • Health Canada has issued no Notice of Compliance and no Drug Identification Number (DIN) for ipamorelin. There is no authorized product and no pharmacy stocks it.
  • It is unapproved in every major jurisdiction, including the United States, the United Kingdom and the European Union, and is Schedule 4 under the TGA in Australia.
  • Clinical development was discontinued, so there is no pending submission and no expected approval date to quote.
  • Volta supplies ipamorelin for in-vitro laboratory research only. It is not a medicine, is not dispensed against a prescription, and is not authorised for human use.
Is ipamorelin approved in Canada?
No. Health Canada has not authorized ipamorelin for any indication. There is no Notice of Compliance and no DIN, so it cannot lawfully be sold as a medicine in Canada and is not stocked by Canadian pharmacies.
Will ipamorelin be approved in Canada?
There is no basis for a date. Clinical development of ipamorelin was discontinued, so no regulatory submission is pending with Health Canada or any other regulator, and there is no expected approval timeline to report.
Can you buy ipamorelin in Canada in 2026?
Not as a medicine. No authorized ipamorelin product exists, so there is nothing a pharmacy can dispense and no prescription that can be written for it. What is sold is research material rather than an approved drug, supplied for in-vitro laboratory use only.

Regulatory position verified 2026-10-10. Positions change; this page states the date it was last checked rather than implying it is current.

More peptides

Ipamorelin sits in Volta's peptides group, alongside the other compounds of the same composition. The whole range is on the full research catalogue, and the library of comparisons and guides is under peptide research.

Research use only. For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Volta does not provide dosing, administration or protocol guidance for any material listed. Read the full research disclaimer.

Cluster last reviewed: 2026-09-15.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.